Published by Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA shall not be responsible for any consequences resulting from the use of this English version.

Revision of PRECAUTIONS

Amoxicillin hydrate Potassium clavulanate/amoxicillin hydrate

May 8, 2024

Therapeutic category

Antibiotic preparations acting mainly on gram-positive and gram-negative bacteria

Non-proprietary name

Amoxicillin hydrate Potassium clavulanate/amoxicillin hydrate

Safety measure

PRECAUTIONS should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>

Revised language is underlined.

Current	Revision
8. IMPORTANT PRECAUTIONS	8. IMPORTANT PRECAUTIONS
No methods are currently available for predicting onset of shock,	No methods are currently available for predicting onset of shock,
anaphylaxis, or acute coronary syndrome accompanying allergic	anaphylaxis, acute coronary syndrome accompanying allergic
reaction with reasonable certainty. A thorough medical interview on	reaction, or drug-induced enterocolitis syndrome with reasonable
information including the patient's medical history of these events,	certainty. A thorough medical interview on information including the
etc. should be conducted in advance. In addition, it should be	patient's medical history of these events, etc. should be conducted
ensured that a history of allergy to antibiotics was checked.	in advance. In addition, it should be ensured that a history of allergy
	to antibiotics was checked.
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1 Clinically Significant Adverse Reactions	11.1 Clinically Significant Adverse Reactions
(N/A)	Drug-induced enterocolitis syndrome
	Allergic gastroenteritis (drug-induced enterocolitis syndrome)
	similar to food protein-induced enterocolitis accompanied by
	diarrhoea, lethargy, facial pallor, hypotension, abdominal pain,
	increased neutrophils, etc., with recurrent vomiting within several
	hours after administration as a main symptom, may occur. Cases
	have been reported mainly in children.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>